We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App





Fujirebio Europe Partners with Centogene to Provide Rapid and High-Quality Preventive SARS-CoV-2 Antigen Testing

By LabMedica International staff writers
Posted on 10 Nov 2020
Print article
Image: Lumipulse G SARS-CoV-2 Ag (Photo courtesy of Fujirebio)
Image: Lumipulse G SARS-CoV-2 Ag (Photo courtesy of Fujirebio)
Fujirebio Europe (Ghent, Belgium) and Centogene N.V. (Rostock, Belgium) have entered into a partnership to leverage LUMIPULSE G technology for large-scale COVID-19 antigen testing with further deployment in German airports.

Lumipulse G SARS-CoV-2 Ag was the first high-sensitive antigen assay launched on a fully automated chemiluminescent platform. It is used on a LUMIPULSE G system for quantitative measurement of SARS-CoV-2 antigen in human nasopharyngeal swab fluid or saliva. It is used as an aid in the diagnosis of a SARS-CoV-2 infection and utilizes proven CLEIA (chemiluminescent enzyme immunoassay) technology. The assay generates fast results (available in up to 40 minutes from sample receipt in the laboratory) using different sample types, including less invasive saliva samples.

Lumipulse G SARS-CoV-2 Ag has been used by Japanese authorities since August this year for quarantine screening of arriving travelers in major international Japanese airports. Centogene has an exclusive cooperation with Lufthansa. As part of the agreement, Fujirebio will supply Lumipulse G SARS-CoV-2 Ag assays running on fully automated CLEIA-based LUMIPULSE G1200 instruments. Sample collection is to be performed by Centogene via the usual oropharyngeal swabs, with the analysis of the samples performed at Centogene test laboratories, and the LUMIPULSE G1200 then supporting by delivering high quality results in up to only 40 minutes from sample receipt in the laboratory. These instruments will be an integrated part of the existing sophisticated automated Centogene workflow that ensures fast and direct delivery of results to customers on their smartphones or digital devices.

“We are very pleased that Centogene has chosen Fujirebio and the Lumipulse G platform to step up their current RT-PCR based COVID-19 testing,” said Christiaan De Wilde, CEO of Fujirebio Europe. “We are certain that the speed, high sensitivity and high quality of the Lumipulse G SARS-CoV-2 Ag testing solution combined with the flexibility of our platform to fit in the existing Centogene workflow will ensure a trustworthy and efficient testing offer.”

“Over the past months, we have seen an increasing need for easily accessible, reliable, and rapid coronavirus tests,” said Dr. Volkmar Weckesser, Chief Information Officer at Centogene. “We have been able to establish a blueprint for this - having set up test centers at four of Germany’s largest airports in the last six months. We are very excited to now expand on these services with the support of Fujirebio’s advanced technology. With this highly validated, customer-friendly solution, we hope to play an integral role in preventing further outbreaks.”



Print article

Channels

Copyright © 2000-2020 Globetech Media. All rights reserved.